Zydus Lifesciences Completes 100% Acquisition of Target Entity

Zydus Lifesciences Limited announced that its wholly owned subsidiary, Zydus MedTech France SAS, has completed the acquisition of 100% share capital and voting rights of the Target Entity. The acquisition was initially announced on July 29, 2025, with Zydus MedTech France acquiring 85.6% of the Target Entity. The remaining 14.4% was acquired on October 24, 2025, through a mandatory tender offer and squeeze-out. This has resulted in the Target Entity becoming a wholly owned subsidiary of Zydus MedTech France. The transaction is considered to be consummated on October 24, 2025. The delay in this intimation is due to the festive holidays of Diwali.